A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

January 19, 2020

Study Completion Date

February 24, 2020

Conditions
Migraine
Interventions
DRUG

Lasmiditan

Administered orally.

Trial Locations (11)

19104

Children's Hospital of Philadelphia, Philadelphia

32751

Meridien Research, Maitland

33143

Qps-Mra, Llc, South Miami

33407

Premiere Research Institute at Palm Beach Neurology, West Palm Beach

34201

Meridien Research, Bradenton

85254

Perserverance Research Center, Scottsdale

92663

Newport Beach Clinical Research Associates, Inc., Newport Beach

06905

New England Institute for Clinical Research, Stamford

830-0011

Kurume Clinical Pharmacology Clinic, Kurume

162-0053

Clinical Research Hospital, Tokyo, Shinjuku-Ku

00912

San Jorge Children and Women's Hospital- Shipping Location, San Juan

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03988088 - A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine | Biotech Hunter | Biotech Hunter